Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...
Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...
The Division of Autonomic Disorders, in conjunction with NYU Langone’s Dysautonomia Center, leads a comprehensive clinical research program dedicated to multiple system atrophy (MSA). As a world-class ...
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results